MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-10-2022
PLx Pharma Operating Income 2011-2026 | PLXP
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income PLx Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -40.8 M | -13.5 M | -14.2 M | -11 M | -15.8 M | -4.81 M | -18.8 M | -13.6 M | -4.01 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.01 M | -40.8 M | -15.2 M |
Quarterly Operating Income PLx Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -10.8 M | -14.5 M | -18.2 M | - | -9.86 M | -6.48 M | -3.6 M | - | -3.19 M | -3.57 M | -3 M | - | -3.68 M | -3.85 M | -2.92 M | - | -2.8 M | -2.4 M | -3.24 M | - | -3.92 M | -4.28 M | -1.35 M | - | -1.05 M | -1.44 M | -5.83 M | - | -5.03 M | -4.03 M | -4.19 M | - | -3.84 M | -3.92 M | -2.54 M | - | -991 K | -363 K | -407 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -363 K | -18.2 M | -4.51 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Assertio Holdings
ASRT
|
-21.5 M | $ 18.02 | -2.12 % | $ 115 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 3.11 | -0.96 % | $ 43.7 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Bausch Health Companies
BHC
|
963 M | $ 5.39 | 0.75 % | $ 1.97 B | Canada |
 |
Harrow Health
HROW
|
30.5 M | $ 37.29 | 1.52 % | $ 1.37 B | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.48 | 1.46 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.09 | 4.81 % | $ 117 M | Canada |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
-32.7 M | $ 4.24 | 3.67 % | $ 273 M | USA |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 8.45 | 0.72 % | $ 433 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-103 M | - | - | $ 193 M | Canada |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.44 | 3.6 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 2.29 | -4.18 % | $ 302 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 23.82 | 2.45 % | $ 1.1 B | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.38 | 1.47 % | $ 3.37 M | Canada |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 7.61 | 8.56 % | $ 300 M | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 0.99 | -0.4 % | $ 49.4 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
Solid Biosciences
SLDB
|
-179 M | $ 8.1 | 1.0 % | $ 709 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 6.72 | -0.44 % | $ 4.15 B | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 2.41 | 5.24 % | $ 2.99 M | USA |
 |
Veru
VERU
|
-36.9 M | $ 2.43 | -4.71 % | $ 328 M | USA |
 |
Viatris
VTRS
|
766 M | $ 13.61 | 0.29 % | $ 16.3 B | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 0.65 | -6.59 % | $ 2.8 M | USA |
 |
Zomedica Corp.
ZOM
|
-84.4 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-4.69 M | $ 0.93 | -0.98 % | $ 33.5 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-3.24 M | $ 0.66 | 5.66 % | $ 2.83 M |  China |
 |
TherapeuticsMD
TXMD
|
-4.39 M | $ 2.05 | - | $ 23.7 M | USA |